Tekmira Pharmaceuticals Corp. has entered into a research collaboration with Bristol-Myers Squibb using Tekmira’s SNALP technology to deliver small interfering RNAs (siRNAs) to specific organs and tissues outside of the liver.     The two companies previously worked together using siRNA delivery technology provided by Protiva Biotherapeutics. In May, Protiva and Tekmira combined their businesses. The collaboration between BMS and Protiva focused on validating certain gene targets using ...